Mathews, C. A., Raashouu-Jensen, N., McCourt, C. K., Frühauf, F., Gilbert, L., Fleming, E. L., Valabrega, G., Cloven, N., Denschlag, D., Podzielinski, I., Boere, I. A., Buscema, J., Pennington, K., Nevadunsky, N. S., Miller, E. M., Shahin, M. S., Antony, G., Austin, L. K., Powell, M. A., Mirza, M. R. (2025). Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.5601